Alpenglow Biosciences and Virdx Announce Strategic Deal to Advance AI-Enabled Prostate Cancer Diagnostics

Portfolio company Alpenglow Biosciences announces a new multi-year collaboration with Virdx, an AI-driven biophysics company specializing in MRI-based cancer detection.

Together, they’re working to bridge radiology and pathology for prostate cancer diagnostics, pairing Virdx’s MRI models with Alpenglow’s whole-tissue 3D light-sheet “ground truth” data to improve diagnostic accuracy and reduce unnecessary interventions.

As CEO Nick Reder shared with investors, “This collaboration will allow Alpenglow to generate large-scale 3D microscopy datasets, full prostate cross-section, to train and validate AI models, capturing rare features and context not visible with routine pathology.”

This partnership underscores how AI, imaging, and 3D pathology are converging to transform precision medicine and accelerate earlier, more accurate cancer detection.